Pharmaceutical The German Institute for Quality and Efficiency in Health Care (IQWiG), which last month had already found an added benefit of the drug for patients with advanced melanoma (The Pharma Letter October 20, now examined in another dossier assessment whether Bristol-Myers Squibb’s Opdivo (nivolumab) also offers an added benefit over the appropriate comparator therapy in the treatment of non-small cell lung cancer (NSCLC). 18 November 2015